Derivatives of magainin and methods of production thereof
The present invention provides a Magainin derivative peptide and method of production thereof. Also provided is a pharmaceutically composition comprising said Magainin derivative peptide and pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents. The Magainin derivative peptide of the present invention having amino acid sequence of the general formula shown as below: Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys- Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-X-Asn-Y-Z-OH in which: X is an amino acid residue selected from the group consisting of Met, Ile and Leu; Y is an amino acid residue selected from the group consisting of Ser, Lys, Ile, Arg and Leu; and Z is Arg.
1. A Magainin derivative peptide having the amino acid sequence of the general formula:
Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Xaa-Asn-Xaa-Arg-OH [SEQ ID NO.: 16] in which:
Xaa at position 21 is an amino acid selected from the group consisting of Met, Ile and Leu;
Xaa at position 23 is an amino acid selected from the group consisting of Ser, Lys, Ile, Leu and Arg, and
wherein Xaa at position 21 is not Met when Xaa at position 23 is Ser.
2. The peptide of claim 1 , wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
3. The peptide of claim 2 , wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 15.
4. The peptide of claim 3 , wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO: 11.
5. The peptide of claim 4 , wherein said peptide has an amino acid sequence as shown in SEQ ID NO: 11.
6. A fusion peptide comprising at least two tandemly linked peptides wherein each amino acid sequence has the general formula shown below:
Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu- lle-Xaa at position 21-Asn-Xaa at position 23-Arg (SEQ ID NO: 16)
in which:
Xaa at position 21 is an amino acid selected from the group consisting of Met, Ile and Leu; and Xaa at position 23 is an amino acid selected from the group consisting of Ser, Lys, Ile, Leu and Arg.
7. A pharmaceutical composition comprising a Magainin derivative peptide of claim 1 and a pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents.
8. A pharmaceutical composition, comprising a Magainin derivative peptide of claim 3 and a pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents.
9. A pharmaceutical composition, comprising a Magainin derivative peptide of claim 4 and a pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents.
10. A pharmaceutical composition, comprising a Magainin derivative peptide of claim 5 and a pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents.